NCT06557122已完成不适用
A Randomized Controlled Clinical Trial Evaluating the Efficacy of a Unique Advanced Bioengineered Skin Substitute With Standard of Care Versus an Active Comparator With Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Encoll Corp6 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年7月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 6
- 主要终点
- Percentage of Wound Area Reduction
研究概览
简要总结
The purpose of this clinical evaluation is to collect patient outcome data on a commercially available 510K FDA cleared advanced skin substitute. The commercially available product is Helicoll® Advanced Skin Substitute.
In this trial two groups of subjects with Wagner 1 diabetic foot ulcers (DFUs), will receive standard of care (SOC) treatment for their condition. Half of the patients will have their SOC treatment with Epifix® or Grafix® and the other half will receive a 510K FDA cleared Helicoll® Advanced Skin Substitute as the primary treatment. The primary endpoint is the percentage wound area reduction of the target ulcer. Secondary endpoints include the proportion of subjects that obtain complete closure over the 5-week treatment period, the time to achieve complete wound closure of the target ulcer by the end of 5 weeks, and mean number of IP applications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be at least 18 years of age or older.
- •Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
- •At randomization, subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 10.0 cm2 measured post debridement using a ruler to measure wound area.
- •The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
- •The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
- •The target ulcer must be full thickness on the foot or ankle that does not probe to bone.
- •Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:
- •TCOM ≥30 mmHg
- •ABI between 0.7 and 1.3
- •PVR: Biphasic
- •As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle of the target extremity.
- •If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and
排除标准
- •will be designated as the target ulcer.
- •The subject must consent to using the prescribed off-loading method for the duration of the study.
- •The subject must agree to attend the twice-weekly/weekly study visits required by the protocol.
- •The subject must be willing and able to participate in the informed consent process.
- •Patients must have read and signed the IRB approved ICF before screening procedures are undertaken.
- •Exclusion Criteria:
- •A subject known to have a life expectancy of < 6 months.
- •If the target ulcer is infected or if there is cellulitis in the surrounding skin.
- •Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
- •A subject has an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
- •A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy.
- •Topical application of steroids to the ulcer surface within one month of initial screening.
- •A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
- •A subject with a glycated hemoglobin (HbA1c) greater than or equal to 13% taken at or within 3 months of the initial screening visit.
- •A subject with a serum creatinine ≥ 3.0mg/dL within 6 months of the initial screening visit.
- •A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer.
- •Women who are pregnant or considering becoming pregnant within the next 6 months.
- •A subject with end stage renal disease requiring dialysis.
- •A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
- •A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.
- •A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit.
- •A subject who has a sensitivity to bovine (cattle) or ovine (sheep) material.
- •A subject that is allergic to aminoglycoside antibiotics (gentamycin, tobramycin, etc.)
结局指标
主要结局
Percentage of Wound Area Reduction
时间窗: 4 weeks
Average Percentage of Wound Area Reduction from Treatment Visit 1 to Treatment Visit 4 measured manually with digital photography
次要结局
- Number of Participants With Repeated Applications(4 weeks)
- Proportion of Complete Closure(5 weeks)
- Time to Achieve Complete Wound Closure(5 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
不适用
Omega3 Wound Fish Skin Graft in the Treatment of DFUsDiabetic Foot UlcerNCT04133493Kerecis Ltd.100
已完成
不适用
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot UlcersUlcer HealingDiabetic Foot UlcerNCT05797285ProgenaCare Global, LLC26
已完成
不适用
ODISEA Trauma: Parental Therapy Dispositive + Videofeedback 3.0Parent-Child RelationsParentingParent-child ProblemNCT04244318Esteban Gómez Muzzio153
终止
不适用
ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access SystemCoronary Artery DiseaseNCT02061696Frank Saltiel39
已完成
不适用
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot UlcersUlcer FootDiabetic FootDiabetic Foot UlcerNCT06403605ETS Wound Care, LLC148